Christine Jessop’s killer identified: Solved cold case raises questions about genetic privacy
By Julia Creet,
The Conversation
| 10. 22. 2020
On Oct. 15, Toronto police announced that they had finally solved the 1984 murder of Christine Jessop using DNA evidence and genetic genealogy websites. Identifying Calvin Hoover as Jessop’s killer has provided immense relief to the family and those close to the case, and in particular to Guy Paul Morin, who was wrongfully convicted and later exonerated after serving 18 months in prison.
The announcement highlights a conundrum: at risk is the genetic privacy of everyone who has uploaded — and, mostly, not uploaded — a DNA sample to a commercial genealogy site.
Genealogists never anticipated that their benign but passionate interest in tracking relations through records and DNA would ever lead to law enforcement’s most potent cold case tool kit. In 2018, public awareness of law enforcement’s mining of genetic genealogy came to light with the 2018 identification of the Golden State Killer. The identification of Joseph James DeAngelo relied on freely uploaded DNA results alongside painstaking genealogical research.
Data industry
Since then, law enforcement’s mining of genealogical data has become an industry in itself, with hundreds...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...